nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—AGTR1—pancreatic cancer	0.513	1	CbGaD
Olmesartan—SLCO1B3—Docetaxel—pancreatic cancer	0.068	0.208	CbGbCtD
Olmesartan—ABCC2—Tamoxifen—pancreatic cancer	0.0619	0.189	CbGbCtD
Olmesartan—SLCO1B1—Irinotecan—pancreatic cancer	0.0541	0.165	CbGbCtD
Olmesartan—ABCC2—Irinotecan—pancreatic cancer	0.0475	0.145	CbGbCtD
Olmesartan—ABCC2—Docetaxel—pancreatic cancer	0.0348	0.107	CbGbCtD
Olmesartan—ABCC2—Sunitinib—pancreatic cancer	0.0347	0.106	CbGbCtD
Olmesartan—ABCC2—Doxorubicin—pancreatic cancer	0.026	0.0794	CbGbCtD
Olmesartan—ABCC2—bile duct—pancreatic cancer	0.0064	0.509	CbGeAlD
Olmesartan—ABCC2—bile—pancreatic cancer	0.00492	0.391	CbGeAlD
Olmesartan—Azilsartan medoxomil—AGTR1—pancreatic cancer	0.00126	0.212	CrCbGaD
Olmesartan—Forasartan—AGTR1—pancreatic cancer	0.00117	0.197	CrCbGaD
Olmesartan—Tasosartan—AGTR1—pancreatic cancer	0.00071	0.12	CrCbGaD
Olmesartan—SLCO1B1—digestive system—pancreatic cancer	0.000708	0.0564	CbGeAlD
Olmesartan—Valsartan—AGTR1—pancreatic cancer	0.000616	0.104	CrCbGaD
Olmesartan—Telmisartan—AGTR1—pancreatic cancer	0.000579	0.0975	CrCbGaD
Olmesartan—ABCC2—digestive system—pancreatic cancer	0.000537	0.0428	CbGeAlD
Olmesartan—Candesartan—AGTR1—pancreatic cancer	0.000467	0.0786	CrCbGaD
Olmesartan—Irbesartan—AGTR1—pancreatic cancer	0.000467	0.0786	CrCbGaD
Olmesartan—Telmisartan—PPARG—pancreatic cancer	0.000364	0.0614	CrCbGaD
Olmesartan—Losartan—AGTR1—pancreatic cancer	0.000301	0.0506	CrCbGaD
Olmesartan—AGTR1—G alpha (q) signalling events—CCK—pancreatic cancer	0.000216	0.0079	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.000215	0.00786	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.000213	0.00782	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCK—pancreatic cancer	0.000213	0.0078	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.000207	0.00758	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.000206	0.00755	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCKAR—pancreatic cancer	0.000204	0.00748	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000204	0.00747	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 signaling events—SRC—pancreatic cancer	0.000203	0.00744	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.000198	0.00724	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.000194	0.0071	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.000193	0.00707	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00019	0.00697	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.000185	0.00678	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—PRLHR—pancreatic cancer	0.000185	0.00676	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.000184	0.00673	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 signaling events—EGFR—pancreatic cancer	0.000178	0.00652	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 trafficking events—CTNNB1—pancreatic cancer	0.000177	0.0065	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000177	0.00648	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.000163	0.00595	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—SST—pancreatic cancer	0.000162	0.00591	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—NFE2L2—pancreatic cancer	0.00016	0.00586	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.00016	0.00586	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—SSTR3—pancreatic cancer	0.000157	0.00575	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000155	0.00569	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—TGFA—pancreatic cancer	0.000153	0.00559	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—SSTR1—pancreatic cancer	0.000151	0.00551	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—SLC2A2—pancreatic cancer	0.000149	0.00547	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—PPY—pancreatic cancer	0.000148	0.00541	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000146	0.00534	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—GCG—pancreatic cancer	0.000146	0.00534	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—SSTR2—pancreatic cancer	0.000145	0.00531	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.000143	0.00523	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CCKBR—pancreatic cancer	0.00014	0.00513	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.000139	0.0051	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.000137	0.00502	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000132	0.00482	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.00013	0.00477	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—pancreatic cancer	0.000127	0.00467	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CXCL8—pancreatic cancer	0.000127	0.00465	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000127	0.00464	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CASP3—pancreatic cancer	0.000122	0.00445	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000119	0.00436	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.000117	0.00427	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—pancreatic cancer	0.000116	0.00425	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—HSPA1A—pancreatic cancer	0.000115	0.00421	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—SCT—pancreatic cancer	0.000114	0.00418	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CCK—pancreatic cancer	0.000109	0.00399	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.000108	0.00397	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CNR2—pancreatic cancer	0.000106	0.00388	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—GLP1R—pancreatic cancer	0.000106	0.00388	CbGpPWpGaD
Olmesartan—Muscle spasms—Docetaxel—pancreatic cancer	0.000105	0.000916	CcSEcCtD
Olmesartan—Eosinophilia—Epirubicin—pancreatic cancer	0.000104	0.000913	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CCKAR—pancreatic cancer	0.000104	0.00382	CbGpPWpGaD
Olmesartan—Pancreatitis—Epirubicin—pancreatic cancer	0.000103	0.000904	CcSEcCtD
Olmesartan—Dizziness—Sunitinib—pancreatic cancer	0.000103	0.000903	CcSEcCtD
Olmesartan—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000103	0.000903	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—VEGFA—pancreatic cancer	0.000103	0.00378	CbGpPWpGaD
Olmesartan—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000103	0.000902	CcSEcCtD
Olmesartan—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000103	0.000899	CcSEcCtD
Olmesartan—Angina pectoris—Epirubicin—pancreatic cancer	0.000103	0.000899	CcSEcCtD
Olmesartan—Abdominal pain—Irinotecan—pancreatic cancer	0.000102	0.000889	CcSEcCtD
Olmesartan—Body temperature increased—Irinotecan—pancreatic cancer	0.000102	0.000889	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000102	0.000889	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000102	0.000889	CcSEcCtD
Olmesartan—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000101	0.000888	CcSEcCtD
Olmesartan—Bronchitis—Epirubicin—pancreatic cancer	0.000101	0.000887	CcSEcCtD
Olmesartan—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000101	0.000883	CcSEcCtD
Olmesartan—Anaemia—Docetaxel—pancreatic cancer	0.000101	0.000881	CcSEcCtD
Olmesartan—Pancytopenia—Epirubicin—pancreatic cancer	0.0001	0.000876	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.0001	0.00366	CbGpPWpGaD
Olmesartan—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	9.95e-05	0.000871	CcSEcCtD
Olmesartan—Vomiting—Sunitinib—pancreatic cancer	9.93e-05	0.000868	CcSEcCtD
Olmesartan—Body temperature increased—Gemcitabine—pancreatic cancer	9.9e-05	0.000866	CcSEcCtD
Olmesartan—Neutropenia—Epirubicin—pancreatic cancer	9.86e-05	0.000863	CcSEcCtD
Olmesartan—Rash—Sunitinib—pancreatic cancer	9.84e-05	0.000861	CcSEcCtD
Olmesartan—Dermatitis—Sunitinib—pancreatic cancer	9.83e-05	0.00086	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Epirubicin—pancreatic cancer	9.8e-05	0.000857	CcSEcCtD
Olmesartan—Urticaria—Fluorouracil—pancreatic cancer	9.78e-05	0.000856	CcSEcCtD
Olmesartan—Headache—Sunitinib—pancreatic cancer	9.78e-05	0.000856	CcSEcCtD
Olmesartan—Syncope—Docetaxel—pancreatic cancer	9.77e-05	0.000855	CcSEcCtD
Olmesartan—Influenza—Doxorubicin—pancreatic cancer	9.76e-05	0.000854	CcSEcCtD
Olmesartan—Leukopenia—Docetaxel—pancreatic cancer	9.75e-05	0.000853	CcSEcCtD
Olmesartan—Body temperature increased—Fluorouracil—pancreatic cancer	9.74e-05	0.000852	CcSEcCtD
Olmesartan—Eosinophilia—Doxorubicin—pancreatic cancer	9.66e-05	0.000845	CcSEcCtD
Olmesartan—Palpitations—Docetaxel—pancreatic cancer	9.62e-05	0.000842	CcSEcCtD
Olmesartan—Photosensitivity reaction—Epirubicin—pancreatic cancer	9.62e-05	0.000842	CcSEcCtD
Olmesartan—Loss of consciousness—Docetaxel—pancreatic cancer	9.57e-05	0.000838	CcSEcCtD
Olmesartan—Pancreatitis—Doxorubicin—pancreatic cancer	9.56e-05	0.000837	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—SHH—pancreatic cancer	9.52e-05	0.00348	CbGpPWpGaD
Olmesartan—Hyperglycaemia—Epirubicin—pancreatic cancer	9.51e-05	0.000832	CcSEcCtD
Olmesartan—Cough—Docetaxel—pancreatic cancer	9.5e-05	0.000832	CcSEcCtD
Olmesartan—Angina pectoris—Doxorubicin—pancreatic cancer	9.5e-05	0.000831	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—pancreatic cancer	9.49e-05	0.00347	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PRLHR—pancreatic cancer	9.48e-05	0.00347	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—TGFB1—pancreatic cancer	9.47e-05	0.00347	CbGpPWpGaD
Olmesartan—Pneumonia—Epirubicin—pancreatic cancer	9.46e-05	0.000827	CcSEcCtD
Olmesartan—Infestation NOS—Epirubicin—pancreatic cancer	9.4e-05	0.000823	CcSEcCtD
Olmesartan—Infestation—Epirubicin—pancreatic cancer	9.4e-05	0.000823	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—IAPP—pancreatic cancer	9.4e-05	0.00344	CbGpPWpGaD
Olmesartan—Bronchitis—Doxorubicin—pancreatic cancer	9.38e-05	0.000821	CcSEcCtD
Olmesartan—Myalgia—Docetaxel—pancreatic cancer	9.27e-05	0.000811	CcSEcCtD
Olmesartan—Chest pain—Docetaxel—pancreatic cancer	9.27e-05	0.000811	CcSEcCtD
Olmesartan—Arthralgia—Docetaxel—pancreatic cancer	9.27e-05	0.000811	CcSEcCtD
Olmesartan—Nausea—Sunitinib—pancreatic cancer	9.27e-05	0.000811	CcSEcCtD
Olmesartan—Pancytopenia—Doxorubicin—pancreatic cancer	9.26e-05	0.000811	CcSEcCtD
Olmesartan—Renal failure—Epirubicin—pancreatic cancer	9.24e-05	0.000809	CcSEcCtD
Olmesartan—Asthenia—Irinotecan—pancreatic cancer	9.23e-05	0.000807	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	9.21e-05	0.000806	CcSEcCtD
Olmesartan—Jaundice—Epirubicin—pancreatic cancer	9.16e-05	0.000802	CcSEcCtD
Olmesartan—Urinary tract infection—Epirubicin—pancreatic cancer	9.14e-05	0.0008	CcSEcCtD
Olmesartan—Neutropenia—Doxorubicin—pancreatic cancer	9.12e-05	0.000798	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	9.07e-05	0.000793	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—PTHLH—pancreatic cancer	9.02e-05	0.0033	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—PTCH1—pancreatic cancer	9.02e-05	0.0033	CbGpPWpGaD
Olmesartan—Asthenia—Gemcitabine—pancreatic cancer	8.99e-05	0.000786	CcSEcCtD
Olmesartan—Haematuria—Epirubicin—pancreatic cancer	8.96e-05	0.000784	CcSEcCtD
Olmesartan—Photosensitivity reaction—Doxorubicin—pancreatic cancer	8.9e-05	0.000779	CcSEcCtD
Olmesartan—Anaphylactic shock—Docetaxel—pancreatic cancer	8.89e-05	0.000778	CcSEcCtD
Olmesartan—Oedema—Docetaxel—pancreatic cancer	8.89e-05	0.000778	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—SSTR3—pancreatic cancer	8.88e-05	0.00325	CbGpPWpGaD
Olmesartan—Pruritus—Gemcitabine—pancreatic cancer	8.86e-05	0.000775	CcSEcCtD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	8.84e-05	0.00324	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—TNF—pancreatic cancer	8.84e-05	0.00324	CbGpPWpGaD
Olmesartan—Infection—Docetaxel—pancreatic cancer	8.83e-05	0.000773	CcSEcCtD
Olmesartan—Sinusitis—Epirubicin—pancreatic cancer	8.82e-05	0.000772	CcSEcCtD
Olmesartan—Hyperglycaemia—Doxorubicin—pancreatic cancer	8.8e-05	0.00077	CcSEcCtD
Olmesartan—Diarrhoea—Irinotecan—pancreatic cancer	8.8e-05	0.00077	CcSEcCtD
Olmesartan—Agranulocytosis—Epirubicin—pancreatic cancer	8.77e-05	0.000768	CcSEcCtD
Olmesartan—Pneumonia—Doxorubicin—pancreatic cancer	8.75e-05	0.000766	CcSEcCtD
Olmesartan—Shock—Docetaxel—pancreatic cancer	8.75e-05	0.000765	CcSEcCtD
Olmesartan—Nervous system disorder—Docetaxel—pancreatic cancer	8.72e-05	0.000763	CcSEcCtD
Olmesartan—Pruritus—Fluorouracil—pancreatic cancer	8.71e-05	0.000762	CcSEcCtD
Olmesartan—Thrombocytopenia—Docetaxel—pancreatic cancer	8.7e-05	0.000762	CcSEcCtD
Olmesartan—Infestation NOS—Doxorubicin—pancreatic cancer	8.7e-05	0.000761	CcSEcCtD
Olmesartan—Infestation—Doxorubicin—pancreatic cancer	8.7e-05	0.000761	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—GDI2—pancreatic cancer	8.69e-05	0.00318	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GDI1—pancreatic cancer	8.69e-05	0.00318	CbGpPWpGaD
Olmesartan—Tachycardia—Docetaxel—pancreatic cancer	8.68e-05	0.000759	CcSEcCtD
Olmesartan—Skin disorder—Docetaxel—pancreatic cancer	8.63e-05	0.000755	CcSEcCtD
Olmesartan—Diarrhoea—Gemcitabine—pancreatic cancer	8.57e-05	0.00075	CcSEcCtD
Olmesartan—Renal failure—Doxorubicin—pancreatic cancer	8.55e-05	0.000748	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—SSTR1—pancreatic cancer	8.51e-05	0.00312	CbGpPWpGaD
Olmesartan—Dizziness—Irinotecan—pancreatic cancer	8.5e-05	0.000744	CcSEcCtD
Olmesartan—Jaundice—Doxorubicin—pancreatic cancer	8.48e-05	0.000742	CcSEcCtD
Olmesartan—Anorexia—Docetaxel—pancreatic cancer	8.47e-05	0.000741	CcSEcCtD
Olmesartan—Rhinitis—Epirubicin—pancreatic cancer	8.46e-05	0.00074	CcSEcCtD
Olmesartan—Urinary tract infection—Doxorubicin—pancreatic cancer	8.45e-05	0.00074	CcSEcCtD
Olmesartan—Diarrhoea—Fluorouracil—pancreatic cancer	8.43e-05	0.000737	CcSEcCtD
Olmesartan—Pharyngitis—Epirubicin—pancreatic cancer	8.38e-05	0.000733	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—PPY—pancreatic cancer	8.34e-05	0.00306	CbGpPWpGaD
Olmesartan—Urinary tract disorder—Epirubicin—pancreatic cancer	8.33e-05	0.000729	CcSEcCtD
Olmesartan—Oedema peripheral—Epirubicin—pancreatic cancer	8.31e-05	0.000727	CcSEcCtD
Olmesartan—Hypotension—Docetaxel—pancreatic cancer	8.31e-05	0.000727	CcSEcCtD
Olmesartan—Haematuria—Doxorubicin—pancreatic cancer	8.29e-05	0.000726	CcSEcCtD
Olmesartan—Connective tissue disorder—Epirubicin—pancreatic cancer	8.29e-05	0.000726	CcSEcCtD
Olmesartan—Urethral disorder—Epirubicin—pancreatic cancer	8.27e-05	0.000724	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—SST—pancreatic cancer	8.25e-05	0.00302	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—SSTR2—pancreatic cancer	8.19e-05	0.003	CbGpPWpGaD
Olmesartan—Vomiting—Irinotecan—pancreatic cancer	8.18e-05	0.000715	CcSEcCtD
Olmesartan—Sinusitis—Doxorubicin—pancreatic cancer	8.16e-05	0.000714	CcSEcCtD
Olmesartan—Dizziness—Fluorouracil—pancreatic cancer	8.14e-05	0.000713	CcSEcCtD
Olmesartan—Agranulocytosis—Doxorubicin—pancreatic cancer	8.12e-05	0.00071	CcSEcCtD
Olmesartan—Rash—Irinotecan—pancreatic cancer	8.11e-05	0.000709	CcSEcCtD
Olmesartan—Dermatitis—Irinotecan—pancreatic cancer	8.1e-05	0.000709	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	8.1e-05	0.000709	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—SSTR3—pancreatic cancer	8.06e-05	0.00295	CbGpPWpGaD
Olmesartan—Headache—Irinotecan—pancreatic cancer	8.06e-05	0.000705	CcSEcCtD
Olmesartan—Insomnia—Docetaxel—pancreatic cancer	8.04e-05	0.000703	CcSEcCtD
Olmesartan—Vomiting—Gemcitabine—pancreatic cancer	7.96e-05	0.000697	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CCKBR—pancreatic cancer	7.91e-05	0.0029	CbGpPWpGaD
Olmesartan—Rash—Gemcitabine—pancreatic cancer	7.9e-05	0.000691	CcSEcCtD
Olmesartan—Dermatitis—Gemcitabine—pancreatic cancer	7.89e-05	0.00069	CcSEcCtD
Olmesartan—Headache—Gemcitabine—pancreatic cancer	7.85e-05	0.000687	CcSEcCtD
Olmesartan—Vomiting—Fluorouracil—pancreatic cancer	7.83e-05	0.000685	CcSEcCtD
Olmesartan—Rhinitis—Doxorubicin—pancreatic cancer	7.83e-05	0.000685	CcSEcCtD
Olmesartan—Dyspepsia—Docetaxel—pancreatic cancer	7.82e-05	0.000685	CcSEcCtD
Olmesartan—Rash—Fluorouracil—pancreatic cancer	7.77e-05	0.000679	CcSEcCtD
Olmesartan—Dermatitis—Fluorouracil—pancreatic cancer	7.76e-05	0.000679	CcSEcCtD
Olmesartan—Pharyngitis—Doxorubicin—pancreatic cancer	7.75e-05	0.000678	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—SSTR1—pancreatic cancer	7.73e-05	0.00283	CbGpPWpGaD
Olmesartan—Decreased appetite—Docetaxel—pancreatic cancer	7.73e-05	0.000676	CcSEcCtD
Olmesartan—Headache—Fluorouracil—pancreatic cancer	7.72e-05	0.000675	CcSEcCtD
Olmesartan—Urinary tract disorder—Doxorubicin—pancreatic cancer	7.71e-05	0.000675	CcSEcCtD
Olmesartan—Oedema peripheral—Doxorubicin—pancreatic cancer	7.69e-05	0.000673	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Docetaxel—pancreatic cancer	7.67e-05	0.000671	CcSEcCtD
Olmesartan—Connective tissue disorder—Doxorubicin—pancreatic cancer	7.67e-05	0.000671	CcSEcCtD
Olmesartan—Fatigue—Docetaxel—pancreatic cancer	7.66e-05	0.000671	CcSEcCtD
Olmesartan—Angiopathy—Epirubicin—pancreatic cancer	7.66e-05	0.00067	CcSEcCtD
Olmesartan—Urethral disorder—Doxorubicin—pancreatic cancer	7.65e-05	0.00067	CcSEcCtD
Olmesartan—Nausea—Irinotecan—pancreatic cancer	7.64e-05	0.000668	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CNR1—pancreatic cancer	7.61e-05	0.00279	CbGpPWpGaD
Olmesartan—Mediastinal disorder—Epirubicin—pancreatic cancer	7.61e-05	0.000665	CcSEcCtD
Olmesartan—Pain—Docetaxel—pancreatic cancer	7.6e-05	0.000665	CcSEcCtD
Olmesartan—Constipation—Docetaxel—pancreatic cancer	7.6e-05	0.000665	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—PPY—pancreatic cancer	7.58e-05	0.00277	CbGpPWpGaD
Olmesartan—Arrhythmia—Epirubicin—pancreatic cancer	7.54e-05	0.00066	CcSEcCtD
Olmesartan—Alopecia—Epirubicin—pancreatic cancer	7.46e-05	0.000653	CcSEcCtD
Olmesartan—Nausea—Gemcitabine—pancreatic cancer	7.44e-05	0.000651	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—SSTR2—pancreatic cancer	7.44e-05	0.00272	CbGpPWpGaD
Olmesartan—Mental disorder—Epirubicin—pancreatic cancer	7.39e-05	0.000647	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—GCG—pancreatic cancer	7.35e-05	0.00269	CbGpPWpGaD
Olmesartan—Malnutrition—Epirubicin—pancreatic cancer	7.35e-05	0.000643	CcSEcCtD
Olmesartan—Feeling abnormal—Docetaxel—pancreatic cancer	7.33e-05	0.000641	CcSEcCtD
Olmesartan—Nausea—Fluorouracil—pancreatic cancer	7.32e-05	0.00064	CcSEcCtD
Olmesartan—Gastrointestinal pain—Docetaxel—pancreatic cancer	7.27e-05	0.000636	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CCKBR—pancreatic cancer	7.18e-05	0.00263	CbGpPWpGaD
Olmesartan—Back pain—Epirubicin—pancreatic cancer	7.11e-05	0.000622	CcSEcCtD
Olmesartan—Angiopathy—Doxorubicin—pancreatic cancer	7.08e-05	0.00062	CcSEcCtD
Olmesartan—Muscle spasms—Epirubicin—pancreatic cancer	7.06e-05	0.000618	CcSEcCtD
Olmesartan—Mediastinal disorder—Doxorubicin—pancreatic cancer	7.04e-05	0.000616	CcSEcCtD
Olmesartan—Body temperature increased—Docetaxel—pancreatic cancer	7.03e-05	0.000615	CcSEcCtD
Olmesartan—Abdominal pain—Docetaxel—pancreatic cancer	7.03e-05	0.000615	CcSEcCtD
Olmesartan—Arrhythmia—Doxorubicin—pancreatic cancer	6.98e-05	0.00061	CcSEcCtD
Olmesartan—Vision blurred—Epirubicin—pancreatic cancer	6.92e-05	0.000606	CcSEcCtD
Olmesartan—Alopecia—Doxorubicin—pancreatic cancer	6.9e-05	0.000604	CcSEcCtD
Olmesartan—Mental disorder—Doxorubicin—pancreatic cancer	6.84e-05	0.000599	CcSEcCtD
Olmesartan—Ill-defined disorder—Epirubicin—pancreatic cancer	6.82e-05	0.000596	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—GAST—pancreatic cancer	6.8e-05	0.00249	CbGpPWpGaD
Olmesartan—Malnutrition—Doxorubicin—pancreatic cancer	6.8e-05	0.000595	CcSEcCtD
Olmesartan—Anaemia—Epirubicin—pancreatic cancer	6.79e-05	0.000594	CcSEcCtD
Olmesartan—Agitation—Epirubicin—pancreatic cancer	6.75e-05	0.000591	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	6.69e-05	0.00245	CbGpPWpGaD
Olmesartan—Malaise—Epirubicin—pancreatic cancer	6.62e-05	0.00058	CcSEcCtD
Olmesartan—Vertigo—Epirubicin—pancreatic cancer	6.6e-05	0.000578	CcSEcCtD
Olmesartan—Syncope—Epirubicin—pancreatic cancer	6.59e-05	0.000576	CcSEcCtD
Olmesartan—Leukopenia—Epirubicin—pancreatic cancer	6.58e-05	0.000575	CcSEcCtD
Olmesartan—Back pain—Doxorubicin—pancreatic cancer	6.58e-05	0.000575	CcSEcCtD
Olmesartan—Muscle spasms—Doxorubicin—pancreatic cancer	6.54e-05	0.000572	CcSEcCtD
Olmesartan—Palpitations—Epirubicin—pancreatic cancer	6.49e-05	0.000568	CcSEcCtD
Olmesartan—Loss of consciousness—Epirubicin—pancreatic cancer	6.46e-05	0.000565	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—SCT—pancreatic cancer	6.45e-05	0.00236	CbGpPWpGaD
Olmesartan—Cough—Epirubicin—pancreatic cancer	6.41e-05	0.000561	CcSEcCtD
Olmesartan—Vision blurred—Doxorubicin—pancreatic cancer	6.41e-05	0.000561	CcSEcCtD
Olmesartan—Asthenia—Docetaxel—pancreatic cancer	6.38e-05	0.000558	CcSEcCtD
Olmesartan—Ill-defined disorder—Doxorubicin—pancreatic cancer	6.31e-05	0.000552	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	6.29e-05	0.0023	CbGpPWpGaD
Olmesartan—Pruritus—Docetaxel—pancreatic cancer	6.29e-05	0.00055	CcSEcCtD
Olmesartan—Anaemia—Doxorubicin—pancreatic cancer	6.28e-05	0.00055	CcSEcCtD
Olmesartan—Arthralgia—Epirubicin—pancreatic cancer	6.25e-05	0.000547	CcSEcCtD
Olmesartan—Chest pain—Epirubicin—pancreatic cancer	6.25e-05	0.000547	CcSEcCtD
Olmesartan—Myalgia—Epirubicin—pancreatic cancer	6.25e-05	0.000547	CcSEcCtD
Olmesartan—Agitation—Doxorubicin—pancreatic cancer	6.25e-05	0.000547	CcSEcCtD
Olmesartan—Anxiety—Epirubicin—pancreatic cancer	6.23e-05	0.000545	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	6.21e-05	0.000543	CcSEcCtD
Olmesartan—Discomfort—Epirubicin—pancreatic cancer	6.18e-05	0.000541	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—GAST—pancreatic cancer	6.18e-05	0.00226	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CCK—pancreatic cancer	6.15e-05	0.00225	CbGpPWpGaD
Olmesartan—Malaise—Doxorubicin—pancreatic cancer	6.13e-05	0.000536	CcSEcCtD
Olmesartan—Vertigo—Doxorubicin—pancreatic cancer	6.11e-05	0.000534	CcSEcCtD
Olmesartan—Syncope—Doxorubicin—pancreatic cancer	6.1e-05	0.000533	CcSEcCtD
Olmesartan—Leukopenia—Doxorubicin—pancreatic cancer	6.08e-05	0.000532	CcSEcCtD
Olmesartan—Diarrhoea—Docetaxel—pancreatic cancer	6.08e-05	0.000532	CcSEcCtD
Olmesartan—Palpitations—Doxorubicin—pancreatic cancer	6.01e-05	0.000526	CcSEcCtD
Olmesartan—Oedema—Epirubicin—pancreatic cancer	6e-05	0.000525	CcSEcCtD
Olmesartan—Anaphylactic shock—Epirubicin—pancreatic cancer	6e-05	0.000525	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CNR2—pancreatic cancer	6e-05	0.0022	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GLP1R—pancreatic cancer	6e-05	0.0022	CbGpPWpGaD
Olmesartan—Loss of consciousness—Doxorubicin—pancreatic cancer	5.97e-05	0.000523	CcSEcCtD
Olmesartan—Infection—Epirubicin—pancreatic cancer	5.96e-05	0.000521	CcSEcCtD
Olmesartan—Cough—Doxorubicin—pancreatic cancer	5.93e-05	0.000519	CcSEcCtD
Olmesartan—Shock—Epirubicin—pancreatic cancer	5.9e-05	0.000516	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CCKAR—pancreatic cancer	5.9e-05	0.00216	CbGpPWpGaD
Olmesartan—Nervous system disorder—Epirubicin—pancreatic cancer	5.88e-05	0.000514	CcSEcCtD
Olmesartan—Dizziness—Docetaxel—pancreatic cancer	5.88e-05	0.000514	CcSEcCtD
Olmesartan—Thrombocytopenia—Epirubicin—pancreatic cancer	5.87e-05	0.000514	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—SCT—pancreatic cancer	5.86e-05	0.00214	CbGpPWpGaD
Olmesartan—Tachycardia—Epirubicin—pancreatic cancer	5.85e-05	0.000512	CcSEcCtD
Olmesartan—Skin disorder—Epirubicin—pancreatic cancer	5.82e-05	0.00051	CcSEcCtD
Olmesartan—Hyperhidrosis—Epirubicin—pancreatic cancer	5.8e-05	0.000507	CcSEcCtD
Olmesartan—Myalgia—Doxorubicin—pancreatic cancer	5.79e-05	0.000506	CcSEcCtD
Olmesartan—Chest pain—Doxorubicin—pancreatic cancer	5.79e-05	0.000506	CcSEcCtD
Olmesartan—Arthralgia—Doxorubicin—pancreatic cancer	5.79e-05	0.000506	CcSEcCtD
Olmesartan—Anxiety—Doxorubicin—pancreatic cancer	5.77e-05	0.000505	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5.75e-05	0.000503	CcSEcCtD
Olmesartan—Discomfort—Doxorubicin—pancreatic cancer	5.72e-05	0.0005	CcSEcCtD
Olmesartan—Anorexia—Epirubicin—pancreatic cancer	5.72e-05	0.0005	CcSEcCtD
Olmesartan—Vomiting—Docetaxel—pancreatic cancer	5.65e-05	0.000495	CcSEcCtD
Olmesartan—Rash—Docetaxel—pancreatic cancer	5.6e-05	0.00049	CcSEcCtD
Olmesartan—Hypotension—Epirubicin—pancreatic cancer	5.6e-05	0.00049	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—PRLHR—pancreatic cancer	5.6e-05	0.00205	CbGpPWpGaD
Olmesartan—Dermatitis—Docetaxel—pancreatic cancer	5.6e-05	0.00049	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CCK—pancreatic cancer	5.59e-05	0.00205	CbGpPWpGaD
Olmesartan—Headache—Docetaxel—pancreatic cancer	5.57e-05	0.000487	CcSEcCtD
Olmesartan—Oedema—Doxorubicin—pancreatic cancer	5.55e-05	0.000485	CcSEcCtD
Olmesartan—Anaphylactic shock—Doxorubicin—pancreatic cancer	5.55e-05	0.000485	CcSEcCtD
Olmesartan—Infection—Doxorubicin—pancreatic cancer	5.51e-05	0.000482	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—PRSS1—pancreatic cancer	5.49e-05	0.00201	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.46e-05	0.000478	CcSEcCtD
Olmesartan—Shock—Doxorubicin—pancreatic cancer	5.46e-05	0.000478	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CNR2—pancreatic cancer	5.44e-05	0.00199	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GLP1R—pancreatic cancer	5.44e-05	0.00199	CbGpPWpGaD
Olmesartan—Nervous system disorder—Doxorubicin—pancreatic cancer	5.44e-05	0.000476	CcSEcCtD
Olmesartan—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.43e-05	0.000475	CcSEcCtD
Olmesartan—Insomnia—Epirubicin—pancreatic cancer	5.42e-05	0.000474	CcSEcCtD
Olmesartan—Tachycardia—Doxorubicin—pancreatic cancer	5.41e-05	0.000474	CcSEcCtD
Olmesartan—Skin disorder—Doxorubicin—pancreatic cancer	5.39e-05	0.000471	CcSEcCtD
Olmesartan—Hyperhidrosis—Doxorubicin—pancreatic cancer	5.36e-05	0.000469	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CCKAR—pancreatic cancer	5.36e-05	0.00196	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—IAPP—pancreatic cancer	5.31e-05	0.00194	CbGpPWpGaD
Olmesartan—Anorexia—Doxorubicin—pancreatic cancer	5.29e-05	0.000463	CcSEcCtD
Olmesartan—Nausea—Docetaxel—pancreatic cancer	5.28e-05	0.000462	CcSEcCtD
Olmesartan—Dyspepsia—Epirubicin—pancreatic cancer	5.28e-05	0.000462	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—ZNRF3—pancreatic cancer	5.26e-05	0.00193	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ACVR1B—pancreatic cancer	5.26e-05	0.00193	CbGpPWpGaD
Olmesartan—Decreased appetite—Epirubicin—pancreatic cancer	5.21e-05	0.000456	CcSEcCtD
Olmesartan—Hypotension—Doxorubicin—pancreatic cancer	5.18e-05	0.000454	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Epirubicin—pancreatic cancer	5.18e-05	0.000453	CcSEcCtD
Olmesartan—Fatigue—Epirubicin—pancreatic cancer	5.17e-05	0.000452	CcSEcCtD
Olmesartan—Pain—Epirubicin—pancreatic cancer	5.13e-05	0.000449	CcSEcCtD
Olmesartan—Constipation—Epirubicin—pancreatic cancer	5.13e-05	0.000449	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—PTHLH—pancreatic cancer	5.1e-05	0.00187	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5.05e-05	0.000442	CcSEcCtD
Olmesartan—Insomnia—Doxorubicin—pancreatic cancer	5.02e-05	0.000439	CcSEcCtD
Olmesartan—Feeling abnormal—Epirubicin—pancreatic cancer	4.94e-05	0.000432	CcSEcCtD
Olmesartan—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.9e-05	0.000429	CcSEcCtD
Olmesartan—Dyspepsia—Doxorubicin—pancreatic cancer	4.88e-05	0.000427	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—SHH—pancreatic cancer	4.88e-05	0.00179	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IAPP—pancreatic cancer	4.82e-05	0.00177	CbGpPWpGaD
Olmesartan—Decreased appetite—Doxorubicin—pancreatic cancer	4.82e-05	0.000422	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.79e-05	0.000419	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	4.79e-05	0.00175	CbGpPWpGaD
Olmesartan—Fatigue—Doxorubicin—pancreatic cancer	4.78e-05	0.000419	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—ARG2—pancreatic cancer	4.76e-05	0.00174	CbGpPWpGaD
Olmesartan—Urticaria—Epirubicin—pancreatic cancer	4.76e-05	0.000417	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—DTX1—pancreatic cancer	4.76e-05	0.00174	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SSTR3—pancreatic cancer	4.76e-05	0.00174	CbGpPWpGaD
Olmesartan—Pain—Doxorubicin—pancreatic cancer	4.74e-05	0.000415	CcSEcCtD
Olmesartan—Constipation—Doxorubicin—pancreatic cancer	4.74e-05	0.000415	CcSEcCtD
Olmesartan—Abdominal pain—Epirubicin—pancreatic cancer	4.74e-05	0.000415	CcSEcCtD
Olmesartan—Body temperature increased—Epirubicin—pancreatic cancer	4.74e-05	0.000415	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—SST—pancreatic cancer	4.66e-05	0.00171	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PTHLH—pancreatic cancer	4.63e-05	0.00169	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PTCH1—pancreatic cancer	4.63e-05	0.00169	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	4.57e-05	0.00167	CbGpPWpGaD
Olmesartan—Feeling abnormal—Doxorubicin—pancreatic cancer	4.57e-05	0.0004	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—SSTR1—pancreatic cancer	4.56e-05	0.00167	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.54e-05	0.000397	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	4.49e-05	0.00165	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PPY—pancreatic cancer	4.48e-05	0.00164	CbGpPWpGaD
Olmesartan—Urticaria—Doxorubicin—pancreatic cancer	4.41e-05	0.000386	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—SSTR2—pancreatic cancer	4.39e-05	0.00161	CbGpPWpGaD
Olmesartan—Body temperature increased—Doxorubicin—pancreatic cancer	4.39e-05	0.000384	CcSEcCtD
Olmesartan—Abdominal pain—Doxorubicin—pancreatic cancer	4.39e-05	0.000384	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CNR1—pancreatic cancer	4.3e-05	0.00158	CbGpPWpGaD
Olmesartan—Asthenia—Epirubicin—pancreatic cancer	4.3e-05	0.000376	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—CCKBR—pancreatic cancer	4.24e-05	0.00155	CbGpPWpGaD
Olmesartan—Pruritus—Epirubicin—pancreatic cancer	4.24e-05	0.000371	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—SST—pancreatic cancer	4.23e-05	0.00155	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	4.22e-05	0.00155	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	4.17e-05	0.00153	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TYMP—pancreatic cancer	4.16e-05	0.00152	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GCG—pancreatic cancer	4.16e-05	0.00152	CbGpPWpGaD
Olmesartan—Diarrhoea—Epirubicin—pancreatic cancer	4.1e-05	0.000359	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	4.04e-05	0.00148	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GLI1—pancreatic cancer	3.99e-05	0.00146	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—DTX4—pancreatic cancer	3.99e-05	0.00146	CbGpPWpGaD
Olmesartan—Asthenia—Doxorubicin—pancreatic cancer	3.98e-05	0.000348	CcSEcCtD
Olmesartan—Dizziness—Epirubicin—pancreatic cancer	3.96e-05	0.000347	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	3.94e-05	0.00144	CbGpPWpGaD
Olmesartan—Pruritus—Doxorubicin—pancreatic cancer	3.92e-05	0.000343	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CNR1—pancreatic cancer	3.91e-05	0.00143	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NRP1—pancreatic cancer	3.88e-05	0.00142	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PPP2R5B—pancreatic cancer	3.88e-05	0.00142	CbGpPWpGaD
Olmesartan—Vomiting—Epirubicin—pancreatic cancer	3.81e-05	0.000334	CcSEcCtD
Olmesartan—Diarrhoea—Doxorubicin—pancreatic cancer	3.8e-05	0.000332	CcSEcCtD
Olmesartan—Rash—Epirubicin—pancreatic cancer	3.78e-05	0.000331	CcSEcCtD
Olmesartan—Dermatitis—Epirubicin—pancreatic cancer	3.78e-05	0.00033	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—GCG—pancreatic cancer	3.77e-05	0.00138	CbGpPWpGaD
Olmesartan—Headache—Epirubicin—pancreatic cancer	3.76e-05	0.000329	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—HEY2—pancreatic cancer	3.74e-05	0.00137	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PRSS1—pancreatic cancer	3.69e-05	0.00135	CbGpPWpGaD
Olmesartan—Dizziness—Doxorubicin—pancreatic cancer	3.67e-05	0.000321	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—GAST—pancreatic cancer	3.65e-05	0.00134	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	3.62e-05	0.00132	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—TGFB1—pancreatic cancer	3.62e-05	0.00132	CbGpPWpGaD
Olmesartan—Nausea—Epirubicin—pancreatic cancer	3.56e-05	0.000312	CcSEcCtD
Olmesartan—Vomiting—Doxorubicin—pancreatic cancer	3.53e-05	0.000309	CcSEcCtD
Olmesartan—Rash—Doxorubicin—pancreatic cancer	3.5e-05	0.000306	CcSEcCtD
Olmesartan—Dermatitis—Doxorubicin—pancreatic cancer	3.49e-05	0.000306	CcSEcCtD
Olmesartan—Headache—Doxorubicin—pancreatic cancer	3.48e-05	0.000304	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—SCT—pancreatic cancer	3.46e-05	0.00127	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HEY1—pancreatic cancer	3.46e-05	0.00127	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.44e-05	0.00126	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GLP1R—pancreatic cancer	3.36e-05	0.00123	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	3.35e-05	0.00122	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—DPYD—pancreatic cancer	3.3e-05	0.00121	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCK—pancreatic cancer	3.3e-05	0.00121	CbGpPWpGaD
Olmesartan—Nausea—Doxorubicin—pancreatic cancer	3.3e-05	0.000288	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—CNR2—pancreatic cancer	3.22e-05	0.00118	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GLP1R—pancreatic cancer	3.22e-05	0.00118	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CXCL8—pancreatic cancer	3.21e-05	0.00118	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ARG2—pancreatic cancer	3.2e-05	0.00117	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCKAR—pancreatic cancer	3.16e-05	0.00116	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC2A2—pancreatic cancer	3.13e-05	0.00115	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.1e-05	0.00114	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JAG2—pancreatic cancer	3.07e-05	0.00112	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MEN1—pancreatic cancer	3.02e-05	0.00111	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.99e-05	0.0011	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SHH—pancreatic cancer	2.88e-05	0.00106	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOTCH4—pancreatic cancer	2.87e-05	0.00105	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IAPP—pancreatic cancer	2.85e-05	0.00104	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TYMP—pancreatic cancer	2.8e-05	0.00102	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTHLH—pancreatic cancer	2.73e-05	0.001	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTCH1—pancreatic cancer	2.73e-05	0.001	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.73e-05	0.000998	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SST—pancreatic cancer	2.5e-05	0.000916	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CG—pancreatic cancer	2.47e-05	0.000903	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JAG1—pancreatic cancer	2.45e-05	0.000896	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOTCH3—pancreatic cancer	2.44e-05	0.000892	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CD44—pancreatic cancer	2.43e-05	0.000888	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.38e-05	0.00087	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.35e-05	0.000862	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GCG—pancreatic cancer	2.33e-05	0.000852	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.31e-05	0.000845	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CNR1—pancreatic cancer	2.31e-05	0.000845	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GLP1R—pancreatic cancer	2.25e-05	0.000826	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CG—pancreatic cancer	2.24e-05	0.00082	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GCG—pancreatic cancer	2.23e-05	0.000816	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—DPYD—pancreatic cancer	2.22e-05	0.000812	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—STK11—pancreatic cancer	2.19e-05	0.000801	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.17e-05	0.000794	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC2A2—pancreatic cancer	2.11e-05	0.000771	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—STK11—pancreatic cancer	2.1e-05	0.000767	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.08e-05	0.000763	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.05e-05	0.000752	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.01e-05	0.000736	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CD—pancreatic cancer	1.97e-05	0.000721	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.89e-05	0.000692	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TYMS—pancreatic cancer	1.88e-05	0.000689	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SMAD4—pancreatic cancer	1.84e-05	0.000672	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.83e-05	0.000671	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CXCL8—pancreatic cancer	1.82e-05	0.000665	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HES1—pancreatic cancer	1.79e-05	0.000656	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.72e-05	0.000628	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CXCL8—pancreatic cancer	1.65e-05	0.000604	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CD44—pancreatic cancer	1.63e-05	0.000597	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.6e-05	0.000585	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.58e-05	0.000579	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TERT—pancreatic cancer	1.57e-05	0.000575	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GCG—pancreatic cancer	1.56e-05	0.000572	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—APOE—pancreatic cancer	1.53e-05	0.00056	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HIF1A—pancreatic cancer	1.5e-05	0.00055	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TSC2—pancreatic cancer	1.5e-05	0.000549	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—STK11—pancreatic cancer	1.47e-05	0.000538	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—APOE—pancreatic cancer	1.47e-05	0.000537	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.45e-05	0.00053	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KDR—pancreatic cancer	1.44e-05	0.000526	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CG—pancreatic cancer	1.38e-05	0.000506	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.38e-05	0.000505	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NFKBIA—pancreatic cancer	1.37e-05	0.0005	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NOTCH1—pancreatic cancer	1.35e-05	0.000495	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PPARG—pancreatic cancer	1.33e-05	0.000488	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CG—pancreatic cancer	1.32e-05	0.000485	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—NRAS—pancreatic cancer	1.32e-05	0.000485	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EGF—pancreatic cancer	1.31e-05	0.000479	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TYMS—pancreatic cancer	1.26e-05	0.000463	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CD—pancreatic cancer	1.21e-05	0.000444	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—EGFR—pancreatic cancer	1.21e-05	0.000441	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CD—pancreatic cancer	1.16e-05	0.000426	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.15e-05	0.000422	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—KRAS—pancreatic cancer	1.14e-05	0.000417	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CB—pancreatic cancer	1.06e-05	0.000387	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTGS2—pancreatic cancer	1.05e-05	0.000384	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.05e-05	0.000383	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—APOE—pancreatic cancer	1.03e-05	0.000376	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CB—pancreatic cancer	1.01e-05	0.000371	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCL8—pancreatic cancer	9.74e-06	0.000357	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	9.73e-06	0.000356	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—HRAS—pancreatic cancer	9.68e-06	0.000354	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—AKT1—pancreatic cancer	9.41e-06	0.000345	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CASP3—pancreatic cancer	9.33e-06	0.000341	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CG—pancreatic cancer	9.28e-06	0.00034	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTEN—pancreatic cancer	9.14e-06	0.000335	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCND1—pancreatic cancer	9.08e-06	0.000332	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CTNNB1—pancreatic cancer	8.99e-06	0.000329	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PPARG—pancreatic cancer	8.95e-06	0.000328	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MMP9—pancreatic cancer	8.81e-06	0.000323	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTEN—pancreatic cancer	8.76e-06	0.000321	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—AKT1—pancreatic cancer	8.55e-06	0.000313	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CD—pancreatic cancer	8.16e-06	0.000299	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SRC—pancreatic cancer	8.13e-06	0.000298	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VEGFA—pancreatic cancer	7.91e-06	0.00029	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—STAT3—pancreatic cancer	7.84e-06	0.000287	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NRAS—pancreatic cancer	7.82e-06	0.000286	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—pancreatic cancer	7.28e-06	0.000267	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFB1—pancreatic cancer	7.26e-06	0.000266	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EGFR—pancreatic cancer	7.12e-06	0.000261	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CB—pancreatic cancer	7.11e-06	0.00026	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTGS2—pancreatic cancer	7.04e-06	0.000258	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KRAS—pancreatic cancer	6.73e-06	0.000246	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CA—pancreatic cancer	6.45e-06	0.000236	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CA—pancreatic cancer	6.18e-06	0.000226	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTEN—pancreatic cancer	6.14e-06	0.000225	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—pancreatic cancer	5.98e-06	0.000219	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HRAS—pancreatic cancer	5.72e-06	0.000209	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—AKT1—pancreatic cancer	5.27e-06	0.000193	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKT1—pancreatic cancer	5.05e-06	0.000185	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CA—pancreatic cancer	4.33e-06	0.000159	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AKT1—pancreatic cancer	3.54e-06	0.00013	CbGpPWpGaD
